Product image of Jazeta (Sitagliptin Hydrochloride) supplied by GNH India

Jazeta

Active Ingredient:
Sitagliptin Hydrochloride
Origin:
EU

Jazeta (Sitagliptin Hydrochloride)

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a DPP-4 inhibitor presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adults.

GNH India supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Jazeta is a DPP‑4 inhibitor used within the type 2 diabetes therapeutic pathway.

  • Type 2 diabetes mellitus (monotherapy): improves glycaemic control when combined with diet and exercise.
  • Type 2 diabetes mellitus (combination therapy): enhances glucose regulation when added to metformin or other antidiabetic agents.
  • Type 2 diabetes mellitus (adjunct therapy): supports overall blood‑sugar management as part of a comprehensive treatment plan.

How It Works

  • Sitagliptin Hydrochloride selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of incretin hormones such as GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion and suppress glucagon release, thereby lowering post‑prandial and fasting blood glucose concentrations.

Side Effects

Adverse reactions may occur with any medication and should be monitored by a healthcare professional.

Common Side Effects

  • Upper respiratory tract infection: mild nasal congestion or sore throat.
  • Headache: transient and usually mild.
  • Nasopharyngitis: inflammation of the nasal passages and throat.
  • Gastrointestinal discomfort: occasional nausea or abdominal pain.
  • Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe hypersensitivity: rash, angioedema, or anaphylaxis.
  • Bullous pemphigoid: blistering skin disorder.
  • Acute renal failure: sudden loss of kidney function in susceptible patients.

Precautions & Warnings

Before initiating therapy, consider the following safety measures.

  • Renal function: assess creatinine clearance and adjust dose if necessary.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Cardiovascular disease: monitor for any worsening of heart conditions.
  • Concomitant medications: review all drugs for potential interactions.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Avoid Interactions

Sitagliptin may interact with other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure.
  • Strong CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely)

  • Insulin or sulfonylureas: heightened risk of hypoglycaemia, monitor glucose levels.
  • Diuretics (e.g., thiazides): may affect renal clearance of sitagliptin.
  • Antihypertensives: observe blood pressure changes when combined with fluid‑retaining agents.

Frequently Asked Questions

Jazeta contains sitagliptin hydrochloride, a DPP‑4 inhibitor that is prescribed to improve blood‑glucose control in adults with type 2 diabetes mellitus, usually as part of a broader regimen that includes diet, exercise and possibly other antidiabetic agents.

Sitagliptin selectively blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances insulin secretion and reduces glucagon release in a glucose‑dependent manner, leading to lower blood‑sugar levels.

The appropriate dose of Jazeta is determined by the prescribing healthcare professional based on the individual’s renal function, glycaemic targets and any concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of sitagliptin during pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Jazeta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycaemia because its insulin‑stimulating effect is glucose‑dependent. Unlike insulin, it is taken orally and does not require injection, offering a convenient option for patients needing additional glycaemic control.

Jazeta should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and keep them out of reach of children.

Jazeta is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious adverse events reported with sitagliptin include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or swelling.

Jazeta is contraindicated in patients with a known hypersensitivity to sitagliptin or any of its excipients. Caution is also advised for individuals with severe renal impairment, a history of pancreatitis, or those taking medications that may cause significant drug‑drug interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT